Page 87 - Human Use News Today

At approval, ruxolitinib cream will be the first treatment for repigmentation in non-segmental vitiligo available in the European Union (EU) In Europe, there are approximately 1.5 million

Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies PARIS, Feb. 24, 2023 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European...

If approved, the JAK inhibitor ruxolitinib cream will be the first repigmentation treatment for non-segmental vitiligo available in the EU.

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) and Ridgeback Biotherapeutics said Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)

(Reuters) - The European Union's drug regulator said on Friday its Committee for Medicinal Products for Human Use has advised against market authorisa...

/PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected...

Key 2022 and post-period events Dr. Paul Stoffelsi appointed as Chief Executive Officer and Chairman of the Board of DirectorsImplemented new strategic direction to accelerate innovation and time-to-patients:

Hepatocellular carcinoma and lung cancer patients are set to benefit from the recent approval of Imfinzi plus Imjudo combinations in the EU.

CAMBRIDGE, Mass., Feb. 23, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ: AKBA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommendi...

Investegate announcements from Galapagos NV, Galapagos announces full year 2022 results and outlook for 2023